Organization | California HIV/AIDS Research Program

California HIV/AIDS Research Program Report issue

Foundation Phase 2 Phase 4

Founded: Oakland CA United States (1983)

Organization Overview

First Clinical Trial

2008

NCT00845676

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

California HIV/AIDS Research Program

Active Ingredients

Drugs in Phase 4 Trials (8)

emtricitabine (emtriva) (4 trials)

interferon alpha-2b (Intron-A) (1 trial)

maraviroc (selzentry) (1 trial)

mesalamine (rowasa) (1 trial)

raltegravir (isentress) (2 trials)

ribavirin (virazole) (1 trial)

tenofovir (viread) (4 trials)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (4)

efavirenz (sustiva) (1 trial)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (1 trial)

telmisartan (micardis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 4)

Coinfection (Phase 4)

Communicable Diseases (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

HIV Infections (Phase 4)

Immune System Diseases (Phase 4)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 4)

Lentivirus Infections (Phase 4)

Sexually Transmitted Diseases (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 12